title: Antidepressant drug prescription and risk of abnormal bleeding: a case-control study.
abstract: This study assessed the risk of any bleeding abnormalities, including the risk of gastrointestinal bleeding, associated with antidepressant exposure. We used a case-control methodology. Case patients were individuals admitted with a diagnosis of abnormal bleeding. Control subjects were individuals admitted on the same date without evidence of abnormal bleeding. During the study period, 11,025 case patients were admitted for bleeding abnormalities (matched with 21,846 eligible control subjects), and 1008 were admitted for gastrointestinal bleeding (matched with 1990 eligible control subjects). With respect to any bleeding abnormalities, antidepressants as a group were not associated with an increased risk (adjusted odds ratio [OR], 0.99; 95% confidence interval [CI], 0.90-1.08). Similarly, selective serotonin reuptake inhibitors as a group, the group of tricyclic and related antidepressants, and the group of other antidepressants were not associated with an increased risk of bleeding. With respect to gastrointestinal bleeding abnormalities, antidepressants as a group were associated with a modestly increased risk (adjusted OR, 1.34; 95% CI, 1.01-1.80). Whereas the group of tricyclic and related antidepressants was not associated with an increased risk of bleeding, the group of selective serotonin reuptake inhibitors was associated with a nonsignificant trend toward an increased risk of bleeding (adjusted OR, 1.31; 95% CI, 0.91-1.88) and the group of other antidepressants with a statistically significant increase in the risk of bleeding (adjusted OR, 1.74; 95% CI, 1.04-2.93). In a population with a low baseline risk of bleeding, we detected a significant increase in the risk of gastrointestinal bleeding only.
authors.affiliation: Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, WHO Collaborating Centre for Research and Training in Mental Health, University of Verona, Italy. corrado.barbui@unoiv
authors.forename: Corrado
authors.initials: C
authors.lastname: Barbui
authors.forename: Margherita
authors.initials: M
authors.lastname: Andretta
authors.forename: Giuseppe
authors.initials: G
authors.lastname: De Vitis
authors.forename: Elisa
authors.initials: E
authors.lastname: Rossi
authors.forename: Fabrizio
authors.initials: F
authors.lastname: D'Arienzo
authors.forename: Luigi
authors.initials: L
authors.lastname: Mezzalira
authors.forename: Marisa
authors.initials: M
authors.lastname: De Rosa
authors.forename: Andrea
authors.initials: A
authors.lastname: Cipriani
authors.forename: Alessandra
authors.initials: A
authors.lastname: Berti
authors.forename: Michela
authors.initials: M
authors.lastname: Nosè
authors.forename: Michele
authors.initials: M
authors.lastname: Tansella
authors.forename: Luigi
authors.initials: L
authors.lastname: Bozzini
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D011307:Drug Prescriptions; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007558:Italy; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000928:Antidepressive Agents